• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    7/30/25 5:01:00 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTHI alert in real time by email
    false 0001979414 0001979414 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported):

    July 24, 2025

     

    NEONC TECHNOLOGIES HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware

    (State or Other Jurisdiction of Incorporation)

     

    001-42567   92-1954864
    (Commission File Number)   (IRS Employer Identification No.)

     

    23975 Park Sorrento, Suite 205 Calabasas, CA   91302
    (Address of Principal Executive Offices)   (Zip Code)

     

    (818) 570-6844

    (Registrant’s Telephone Number, Including Area Code)

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Stock, par value $0.0001   NTHI   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01Entry into a Material Definitive Agreement.

     

    On July 24, 2025, NeOnc Technologies Holdings, Inc. (the “Company”) entered into a binding letter of intent (the “LOI”) with Dr. Ishwar Puri and Beth Levinson (together, the “Holders”), whereby the Company will acquire all of the equity interest of the to-be-formed Delaware limited liability Company (the “LLC”) from the Holders in a share exchange transaction (the “Proposed Transaction”). Pursuant to the LOI, the Holders will form the LLC which will be owned by the Holders and the Holders will contribute certain intellectual property and other assets to the LLC in exchange for the equity in the LLC. Thereafter, the LLC will enter into a Patent Transfer Agreement with McMaster University to acquire US Patent No 11,788,057 B2 (the “Patent”). The consideration for such acquisition will be $500,000 in cash. The Company will issue the LLC a promissory note in the amount of $500,000 (the “Note”) to fund the purchase of the Patent. Upon closing of the Proposed Transaction, the Company shall forgive the Note.

     

    The purchase price for the Proposed Transaction will be: an amount of shares of Company common stock equal to (a) 120,000 shares of Company common stock with an attributed value of $25 per share, less (b) an amount of shares equal to (x) the aggregate transaction fees incurred by the Company in connection with all of the transactions referenced in the LOI divided by (y) $25.00, rounded up to the nearest whole share.

     

    The Proposed Transaction is subject to, among other things, the formation of the LLC, the completion of due diligence investigations by the Company, and the execution of the Patent Transfer Agreement between the LLC and McMaster University.

     

    Lastly, in connection with the closing of the Proposed Transaction, Dr. Ishwar K. Puri will be appointed to the Company’s Board of Directors.

     

    The foregoing description of the LOI is not complete and is qualified in its entirety by reference to the LOI, a copy of which is filed as Exhibit 10.1 to this Current Report.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    10.1   Letter of Intent dated July 24, 2025, between the Company, Dr. Ishwar Puri and Beth Levinson
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: July 30, 2025 NeOnc Technologies Holdings, Inc.
         
      By: /s/ Amir Heshmatpour
        Name: Amir Heshmatpour
        Title: President and Executive Chairman

     

    2

    Get the next $NTHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTHI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NTHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $119,600 worth of CommonStock (20,000 units at $5.98) and bought $65,060 worth of shares (10,000 units at $6.51), increasing direct ownership by 1% to 2,992,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 9:10:01 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Chiang Ming-Fu (Alan) claimed ownership of 2,190,049 shares (SEC Form 3)

    3 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 6:13:12 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $7,359 worth of shares (1,100 units at $6.69), increasing direct ownership by 0.83% to 134,260 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 5:46:38 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    SEC Filings

    View All

    SEC Form 424B5 filed by NeOnc Technologies Holdings Inc.

    424B5 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    2/12/26 4:51:40 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by NeOnc Technologies Holdings Inc.

    S-1 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    2/6/26 4:48:06 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

    8-K - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Filer)

    1/29/26 3:04:39 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Heshmatpour Amir F bought $119,600 worth of CommonStock (20,000 units at $5.98) and bought $65,060 worth of shares (10,000 units at $6.51), increasing direct ownership by 1% to 2,992,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 9:10:01 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Clinical Officer Neman-Ebrahim Yousha bought $7,359 worth of shares (1,100 units at $6.69), increasing direct ownership by 0.83% to 134,260 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    11/24/25 5:46:38 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

    4 - NEONC TECHNOLOGIES HOLDINGS, INC. (0001979414) (Issuer)

    5/23/25 9:31:11 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

    CALABASAS, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") for the purchase and sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares of common stock at a per share exercise price of $9.00 at a combined purchase price of $7.20, that is expected to result in gross proceeds of up to approximately $16 million to the Company. NeO

    1/30/26 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Reports Updated Clinical Results

    CALABASAS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. Since the Company's prior announcement and 8K event on November 12, 2025, an additional patient has achieved both durable long-term survival and radiographic remission, further strengthening the clinical signal observed with intranasal NEO100

    12/15/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors

    CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly published preclinical findings from a research collaboration at the University of Southern California (USC). The study, now available on bioRxiv (https://www.biorxiv.org/content/10.1101/2025.11.25.690556v1), demonstrates that ultrasound further enhances and amplifies NEO100's therapeutic potency, driving strong antitumor effects across multiple primary and metastatic brain tumor types. Utilizing an AI-driven, 3D-bioprinted New Approach Methodol

    12/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Financials

    Live finance-specific insights

    View All

    NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update

    CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Third Quarter & Recent Corporate Highlights Middle East – NuroMENA, the UAE-based subsidiary, advanced its regional partnerships by appointing His Highness Sheikh Nahyan bin Zayed Al Nahyan as Executive Chairman, signing a Master Services Agreement with M42's IROS, and completing ADGM incorpora

    11/14/25 4:01:00 PM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)

    CALABASAS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company's lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1 (IDH1)–mutant high-grade glioma (WHO Grade III and IV). The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026. "Compl

    11/13/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

    CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, members of the NTHI management team and independent members of the company's Scientific Advisory Board (SAB) will present data updates from the Company's ongoing Phase 1/2a NEO100-1 clinical trial and

    11/7/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NTHI
    Leadership Updates

    Live Leadership Updates

    View All

    NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth

    CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that its Board of Directors has appointed Amir Heshmatpour as Chief Executive Officer. Mr. Heshmatpour, who was appointed President in April, will assume the CEO role effective immediately, continuing to serve as Executive Chairman of the Board. Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Di

    11/4/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board

    CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour, Executive Chairman & President, of NeOnc Technologies, commented, "We are privileged to have Dr. David M. Ashley MBBS (Hons), FRACP, PhD, of Duke University on NeOnc's Scientific Adv

    10/2/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, to Its Scientific Advisory Board

    CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced the appointment of Dr. Alexandra M. Miller to its scientific advisory board. Dr. Miller is the Chief of the Neuro-oncology Program and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health's Perlmutter Cancer Center, where she specializes in treating patients with primary brain tumors. "We are thrilled to welcome Dr. Alexandra Miller to our Scientific Advisory Board," said Amir F. Heshmatpour, Executive Chairman and P

    10/1/25 9:00:00 AM ET
    $NTHI
    Biotechnology: Pharmaceutical Preparations
    Health Care